A 58-year-old man with stage IV renal cell carcinoma (clear cell type) with pulmonary and bone metastases presents for systemic therapy. He has no prior systemic treatment. What is the drug of choice for first-line treatment?

Question

Accepted Answer

A. Sunitinib. ## First-Line Systemic Therapy for Metastatic RCC

**Key Point:** Sunitinib is the preferred first-line tyrosine kinase inhibitor (TKI) for treatment-naïve patients with metastatic clear cell renal cell carcinoma.

### Mechanism of Action
Sunitinib is a multi-targeted TKI that inhibits:
- VEGFR (vascular endothelial growth factor receptor)
- PDGFR (platelet-derived growth factor receptor)
- c-KIT
- RET

These targets are critical in RCC pathogenesis, particularly in clear cell histology where VHL inactivation leads to HIF-α accumulation and VEGF overexpression.

### Evidence Base

| Feature | Sunitinib | Sorafenib | Pazopanib |
|---------|-----------|-----------|----------|
| **First-line approval** | Yes (FDA & NCCN) | Second-line | Yes (alternative) |
| **Median PFS** | 11 months | 5.5 months | 9.2 months |
| **Median OS** | 26.4 months | 17.8 months | 29.3 months |
| **Standard dosing** | 50 mg daily (4 weeks on, 2 weeks off) | 400 mg BD daily | 800 mg daily |
| **Key advantage** | Superior PFS in treatment-naïve | Better for sorafenib-experienced | Oral bioavailability |

**High-Yield:** Sunitinib is the **gold standard first-line TKI** for metastatic clear cell RCC based on the pivotal SUTENT trial (2007), which demonstrated superior progression-free survival compared to interferon-alpha.

### Clinical Pearl
Sunitinib's intermittent dosing schedule (4 weeks on, 2 weeks off) allows for dose recovery and tolerability management—a practical advantage in real-world practice.

### Toxicity Profile
- Hypertension (30–40%)
- Hand-foot skin reaction
- Fatigue
- Diarrhea
- Cardiac dysfunction (rare but serious)

**Tip:** Always monitor BP and cardiac function (echocardiography baseline) before starting sunitinib.

Answer

B. Sorafenib

Answer

C. Bevacizumab

Answer

D. Pazopanib

A 58-year-old man with stage IV renal cell carcinoma (clear cell type) with pulmonary and bone metastases presents for systemic therapy. He has no prior systemic treatment. What is the drug of choice for first-line treatment?

Explanation

First-Line Systemic Therapy for Metastatic RCC

Mechanism of Action

Evidence Base

Clinical Pearl

Toxicity Profile

Practice similar questions

Join our NEET PG community

Feature	Sunitinib	Sorafenib	Pazopanib
First-line approval	Yes (FDA & NCCN)	Second-line	Yes (alternative)
Median PFS	11 months	5.5 months	9.2 months
Median OS	26.4 months	17.8 months	29.3 months
Standard dosing	50 mg daily (4 weeks on, 2 weeks off)	400 mg BD daily	800 mg daily
Key advantage	Superior PFS in treatment-naïve	Better for sorafenib-experienced	Oral bioavailability